Skip to main content

Table 7 Non-orphan oncology drugs and indications.

From: Establishing a reasonable price for an orphan drug

Name Indication
Lonsurf To treat adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and an anti-EGFR therapy
Kadcyla To treat (adult) patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane
Xofigo To treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs
Inlyta To treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer
Perjeta To treat patients with HER2-positive late-stage (metastatic) breast cancer in combination with Herceptin and docetaxel
Xtandi To treat men with late-stage (metastatic) castration-resistant prostate cancer who have received docetaxel therapy
Zytiga In combination with prednisone (a steroid) to treat patients with late-stage (metastatic) castration-resistant prostate cancer who have received prior docetaxel (chemotherapy)